« Previous AbstractTemporal effects of hunting on foraging behavior of an apex predator: Do bears forego foraging when risk is high?    Next AbstractQuantitative self-assessment of exposure to solvents among shoe repair men »

Clin Oral Investig

Title:		Volatile organic compounds in the breath of oral candidiasis patients: a pilot study
Author(s):		Hertel M; Schuette E; Kastner I; Hartwig S; Schmidt-Westhausen AM; Preissner R; Paris S; Preissner S;
Address:		"Department of Oral Medicine, Dental Radiology and Oral Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany. Department of Operative and Preventive Dentistry, Charite Universitatsmedizin Berlin, Berlin, Germany. Department of Oral and Maxillofacial Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany. Structural Bioinformatics Group, Institute of Physiology, Charite Universitatsmedizin Berlin & ECRC, Berlin, Germany. Department of Operative and Preventive Dentistry, Charite Universitatsmedizin Berlin, Berlin, Germany. saskia.preissner@charite.de"
Journal Title:		Clin Oral Investig
Year:		2018
Volume:		20170610
Issue:		2
Page Number:		721 - 731
DOI:		10.1007/s00784-017-2147-6
ISSN/ISBN:		1436-3771 (Electronic) 1432-6981 (Linking)
Abstract:		"OBJECTIVES: The aim of the study was to investigate whether specific volatile organic compounds (VOCs) can be detected in oral candidiasis patients using breath analysis in order to develop a point-of-care diagnostic tool. PATIENTS/METHODS: Breath samples of 10 diseased patients and 10 subjects carrying no Candida spp. were analyzed using gas chromatography and mass spectrometry. In infected patients, breath tests were performed before and after antifungal therapy. RESULTS: Breath testing was positive for 143 volatiles in both healthy subjects and diseased patients. Among those, specific signature volatiles known to be emitted by Candida spp. in vitro were not detected. Even though no specific signature was retrieved from the diseased patients, a pattern containing nine compounds (2-methyl-2-butanol, hexanal, longifolene, methyl acetate, 1-heptene, acetophenone, decane, 3-methyl-1-butanol, chlorbenzene) was identified, which showed characteristic changes after antifungal therapy. CONCLUSIONS: Focusing on the identified pattern, breath analysis may be applied to confirm the absence of Candida spp. after therapy in terms of a confirmatory test supplementing clinical examination, thereby replacing microbial testing. However, microbial testing will still be needed to initially confirm clinical diagnoses, as no specific signature was found. CLINICAL RELEVANCE: A breath test may help in avoiding extended antifungal administration resulting in resistance development and might be useful in the monitoring of disease recurrences in vulnerable groups"
Keywords:		"Aged Aged, 80 and over Antifungal Agents/therapeutic use Breath Tests Candidiasis, Oral/drug therapy/*metabolism Case-Control Studies Dentures Female Gas Chromatography-Mass Spectrometry Humans Male Mass Spectrometry Middle Aged Pilot Projects Volatile Or;"
Notes:		"MedlineHertel, Moritz Schuette, Eyke Kastner, Isabell Hartwig, Stefan Schmidt-Westhausen, Andrea Maria Preissner, Robert Paris, Sebastian Preissner, Saskia eng Germany 2017/06/12 Clin Oral Investig. 2018 Mar; 22(2):721-731. doi: 10.1007/s00784-017-2147-6. Epub 2017 Jun 10"